CML32 Antibody

Overview of CD32 (FcγRII)

CD32 is a low-affinity Fc gamma receptor expressed on immune cells (B lymphocytes, neutrophils, macrophages, NK cells) and platelets. It binds aggregated IgG or immune complexes, mediating phagocytosis, cytokine release, and immune modulation .

CD32 Isoforms and Their Roles

CD32 exists in three isoforms with distinct functions:

CD32B is critical in autoimmune regulation and is a therapeutic target for diseases like systemic lupus erythematosus (SLE) .

Clinically Relevant Anti-CD32 Antibodies

Therapeutic Applications

• Cancer: Anti-CD32B antibodies (e.g., 2B6) deplete clonal plasma cells in systemic light-chain amyloidosis (AL), with 99% CD32B expression observed in patient-derived cells .

• Autoimmunity: CD32B agonists suppress B-cell hyperactivity in SLE .

CD32B in AL Amyloidosis

• Expression: 99% of clonal plasma cells in AL patients express CD32B .

• Therapy: Humanized 2B6 monoclonal antibody induces apoptosis in CD32B+ cells via ADCC/CDC mechanisms .

Functional Blockade

• 6C4 Antibody: Inhibits IgG binding to CD32A/B, reducing inflammatory responses in arthritis models .

Challenges and Future Directions

• Specificity: Many anti-CD32 antibodies cross-react between isoforms, necessitating engineered clones like 2B6 for precision .

• Clinical Trials: Anti-CD32B therapies (e.g., 2B6) are in early-phase trials for AL amyloidosis and B-cell malignancies .